Lance Smith, Author at Clinical Trial Recruitment

GIOSTAR in Process of US FDA Approval for Type 2 Diabetes Clinical Trial

by Lance Smith | Dec 11, 2019 | Study Scavenger Clinical Trial Recruitment Platform

Groundbreaking study by pioneer in stem cell research may potentially save millions of lives SAN DIEGO, Dec. 10, 2019 /PRNewswire/ — Global Institute of Stem Cell Therapy and Research (GIOSTAR), the leader in regenerative technologies, is proud to announce that...

Synlogic Bridging Study Data with Solid Oral Formulation of SYNB1618, a Synthetic Biotic Approach to Treat Phenylketonuria, Demonstrate Improved Tolerability over Early Liquid Formulation and Guide to Next Stage of Clinical Development

by Lance Smith | Dec 11, 2019 | Study Scavenger Clinical Trial Recruitment Platform

– Company expects to initiate Phase 2 clinical trial in patients with phenylketonuria in 1H 2020 – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel,...

Iterum Therapeutics Announces Topline Results from Phase 3 Clinical Trial of Oral and IV Sulopenem for the Treatment of Complicated Intra-abdominal Infections

by Lance Smith | Dec 11, 2019 | Study Scavenger Clinical Trial Recruitment Platform

Email Print Friendly Share December 10, 2019 16:10 ET | Source: Iterum Therapeutics plc DUBLIN, Ireland and CHICAGO, Dec. 10, 2019 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing an oral...

Hepion Pharmaceuticals Successfully Advances to Next Dosing Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431

by Lance Smith | Dec 11, 2019 | Study Scavenger Clinical Trial Recruitment Platform

EDISON, NJ / ACCESSWIRE / December 10, 2019 / Hepion Pharmaceuticals, Inc. (NASDAQ: HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (“NASH”),...

Innovation Pharmaceuticals Provides Update on Clinical Trials and Revenue Potential of Brilacidin in Inflammatory Bowel Diseases

by Lance Smith | Dec 11, 2019 | Study Scavenger Clinical Trial Recruitment Platform

BEVERLY, Mass., Dec. 10, 2019 (GLOBE NEWSWIRE) — Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, is pleased to inform shareholders that Alfasigma S.p.A (“Alfasigma”), the licensee of Brilacidin for the treatment...

« Older Entries

Next Entries »